Prognostic impact of atrial fibrillation in patients undergoing transcatheter aortic valve implantation

IF 2.9 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Heart Rhythm O2 Pub Date : 2025-03-01 DOI:10.1016/j.hroo.2024.12.016
Jakob J. Reichl MD , Thorald Stolte , Jasper Boeddinghaus MD, Max Wagener MD, Gregor Leibundgut MD, Patrick Badertscher MD, Christian Sticherling MD, Michael Kühne MD, Christoph Kaiser MD, Felix Mahfoud MD, Thomas Nestelberger MD
{"title":"Prognostic impact of atrial fibrillation in patients undergoing transcatheter aortic valve implantation","authors":"Jakob J. Reichl MD ,&nbsp;Thorald Stolte ,&nbsp;Jasper Boeddinghaus MD,&nbsp;Max Wagener MD,&nbsp;Gregor Leibundgut MD,&nbsp;Patrick Badertscher MD,&nbsp;Christian Sticherling MD,&nbsp;Michael Kühne MD,&nbsp;Christoph Kaiser MD,&nbsp;Felix Mahfoud MD,&nbsp;Thomas Nestelberger MD","doi":"10.1016/j.hroo.2024.12.016","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Atrial fibrillation (AF) is the most common arrhythmia and an important risk factor for adverse cardiac outcomes, including heart failure and stroke. Moreover, AF has been linked to worse outcomes after transcatheter aortic valve implantation (TAVI). Real-world data on the impact of AF on outcomes after TAVI remain limited.</div></div><div><h3>Objective</h3><div>To assess the impact of AF on periprocedural and short-term outcomes after TAVI.</div></div><div><h3>Methods</h3><div>Patients undergoing TAVI at a tertiary center were consecutively included in a prospective registry. Cardiac rhythm at baseline was assessed using 12-lead ECGs. The primary outcome was all-cause mortality at 30 days. Secondary outcomes included all-cause mortality at 1 year, stroke at 30 days and 1 year, and procedural success, defined as freedom from periprocedural mortality, surgical re-interventions, re-interventions of the aortic valve, major access site complications, and periprocedural bleedings until discharge.</div></div><div><h3>Results</h3><div>Among 1655 patients undergoing TAVI, 428 patients (25.6%) had preexisting AF, and 77 patients (4.6%) were diagnosed with new-onset AF during hospitalization for TAVI. AF was not associated with higher mortality at 30 days (3.7% vs 2.0%; <em>P</em> = .054, adjusted hazard ratio [aHR], 1.8 [95% confidence interval (CI), 0.9–3.4]), but at 1 year (13.8% vs 8.4%; <em>P</em> = .001; aHR, 1.6 [95%CI, 1.2–2.2]). The stroke rate was higher in patients with AF at 30 days (5.9% vs 2.7%; <em>P</em> = .003; aHR, 2.1 [95%CI, 1.2–3.5]) and at 1 year (7.1% vs 3.8%; <em>P</em> = .005; aHR, 1.8 [95%CI, 1.2–2.9]). At discharge, 452 patients (89.5%) with AF received oral anticoagulation. After adjusting for anticoagulant therapy, the difference in stroke risk at 30 days (5.7% vs 2.3%; <em>P</em> = .058) and 1 year (6.8% vs 4.2%; <em>P</em> = .165) was no longer significant. Patients with AF experienced more major or life-threatening bleeding complications (14.2% vs 10.6%; <em>P</em> = .043). There were no differences in procedural success between patients with and those without AF (78.8% vs 78.3%; <em>P</em> = .886).</div></div><div><h3>Conclusion</h3><div>AF was associated with increased mortality at 1 year and higher rates of stroke and major bleeding at 30 days and 1 year after TAVI.</div></div>","PeriodicalId":29772,"journal":{"name":"Heart Rhythm O2","volume":"6 3","pages":"Pages 273-279"},"PeriodicalIF":2.9000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Heart Rhythm O2","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666501825000091","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Atrial fibrillation (AF) is the most common arrhythmia and an important risk factor for adverse cardiac outcomes, including heart failure and stroke. Moreover, AF has been linked to worse outcomes after transcatheter aortic valve implantation (TAVI). Real-world data on the impact of AF on outcomes after TAVI remain limited.

Objective

To assess the impact of AF on periprocedural and short-term outcomes after TAVI.

Methods

Patients undergoing TAVI at a tertiary center were consecutively included in a prospective registry. Cardiac rhythm at baseline was assessed using 12-lead ECGs. The primary outcome was all-cause mortality at 30 days. Secondary outcomes included all-cause mortality at 1 year, stroke at 30 days and 1 year, and procedural success, defined as freedom from periprocedural mortality, surgical re-interventions, re-interventions of the aortic valve, major access site complications, and periprocedural bleedings until discharge.

Results

Among 1655 patients undergoing TAVI, 428 patients (25.6%) had preexisting AF, and 77 patients (4.6%) were diagnosed with new-onset AF during hospitalization for TAVI. AF was not associated with higher mortality at 30 days (3.7% vs 2.0%; P = .054, adjusted hazard ratio [aHR], 1.8 [95% confidence interval (CI), 0.9–3.4]), but at 1 year (13.8% vs 8.4%; P = .001; aHR, 1.6 [95%CI, 1.2–2.2]). The stroke rate was higher in patients with AF at 30 days (5.9% vs 2.7%; P = .003; aHR, 2.1 [95%CI, 1.2–3.5]) and at 1 year (7.1% vs 3.8%; P = .005; aHR, 1.8 [95%CI, 1.2–2.9]). At discharge, 452 patients (89.5%) with AF received oral anticoagulation. After adjusting for anticoagulant therapy, the difference in stroke risk at 30 days (5.7% vs 2.3%; P = .058) and 1 year (6.8% vs 4.2%; P = .165) was no longer significant. Patients with AF experienced more major or life-threatening bleeding complications (14.2% vs 10.6%; P = .043). There were no differences in procedural success between patients with and those without AF (78.8% vs 78.3%; P = .886).

Conclusion

AF was associated with increased mortality at 1 year and higher rates of stroke and major bleeding at 30 days and 1 year after TAVI.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
心房颤动对经导管主动脉瓣置入术患者预后的影响
房颤(AF)是最常见的心律失常,也是心脏不良结局(包括心力衰竭和中风)的重要危险因素。此外,房颤与经导管主动脉瓣植入术(TAVI)后较差的预后有关。关于房颤对TAVI后预后影响的实际数据仍然有限。目的评价心房纤颤对TAVI术后围手术期及短期预后的影响。方法在三级中心接受TAVI的患者连续纳入前瞻性登记。使用12导联心电图评估基线时的心律。主要终点是30天的全因死亡率。次要结局包括1年全因死亡率,30天和1年卒中,手术成功,定义为术中死亡、手术再干预、主动脉瓣再干预、主要通路并发症和术中出血直到出院。结果1655例TAVI患者中,428例(25.6%)患者既往存在房颤,77例(4.6%)患者在TAVI住院期间被诊断为新发房颤。房颤与30天的高死亡率无关(3.7% vs 2.0%;P = 0.054,校正风险比[aHR], 1.8[95%可信区间(CI), 0.9-3.4]),但1年后(13.8% vs 8.4%;P = .001;aHR, 1.6 [95%CI, 1.2-2.2])。房颤患者30天卒中发生率更高(5.9% vs 2.7%;P = .003;aHR, 2.1 [95%CI, 1.2-3.5])和1年(7.1% vs 3.8%;P = 0.005;aHR, 1.8 [95%CI, 1.2 ~ 2.9])。出院时,452例(89.5%)房颤患者接受口服抗凝治疗。调整抗凝治疗后,30天卒中风险差异(5.7% vs 2.3%;P = 0.058)和1年(6.8% vs 4.2%;P = .165)不再显著。房颤患者出现更多严重或危及生命的出血并发症(14.2% vs 10.6%;P = .043)。有房颤和无房颤患者的手术成功率没有差异(78.8% vs 78.3%;P = .886)。结论房颤与TAVI术后1年死亡率增高、30天和1年卒中和大出血发生率增高有关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Heart Rhythm O2
Heart Rhythm O2 Cardiology and Cardiovascular Medicine
CiteScore
3.30
自引率
0.00%
发文量
0
审稿时长
52 days
期刊最新文献
Differential subclinical hemolysis after pulsed field ablation using the FARAPULSE pentaspline catheter vs the PulseSelect circular multi-electrode array catheter Assessment of incomplete lesions using 3-dimensional mapping following pentaspline pulsed field ablation for atrial fibrillation High-amplitude pacing can identify epicardial connections in the posterior wall during ablation for atrial fibrillation The usefulness of catheter ablation even in patients with myocardial impairment: Myocardial extracellular volume assessed by preablation planning computed tomography cannot predict atrial fibrillation recurrence Clonal hematopoiesis of indeterminate potential as a risk factor for atrial fibrillation: Evidence of a causal relationship by Mendelian randomization study
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1